FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3202801096> ?p ?o ?g. }

• W3202801096 endingPage "813" @default.
• W3202801096 startingPage "800" @default.
• W3202801096 abstract "Background Embryonal tumours with multi-layered rosettes (ETMRs) are a newly recognised, rare paediatric brain tumour with alterations of the C19MC microRNA locus. Due to varied diagnostic practices and scarce clinical data, disease features and determinants of outcomes for these tumours are poorly defined. We did an integrated clinicopathological and molecular analysis of primary ETMRs to define clinical phenotypes, and to identify prognostic factors of survival and key treatment modalities for this orphan disease. Methods Paediatric patients with primary ETMRs and tissue available for analyses were identified from the Rare Brain Tumor Consortium global registry. The institutional histopathological diagnoses were centrally re-reviewed as per the current WHO CNS tumour guidelines, using histopathological and molecular assays. Only patients with complete clinical, treatment, and survival data on Nov 30, 2019, were included in clinicopathological analyses. Among patients who received primary multi-modal curative regimens, event-free survival and overall survival were determined using Cox proportional hazard and log-rank analyses. Univariate and multivariable Cox proportional hazard regression was used to estimate hazard ratios (HRs) with 95% CIs for clinical, molecular, or treatment-related prognostic factors. Findings 159 patients had a confirmed molecular diagnosis of primary ETMRs (median age at diagnosis 26 months, IQR 18–36) and were included in our clinicopathological analysis. ETMRs were predominantly non-metastatic (94 [73%] of 128 patients), arising from multiple sites; 84 (55%) of 154 were cerebral tumours and 70 (45%) of 154 arose at sites characteristic of other brain tumours. Hallmark C19MC alterations were seen in 144 (91%) of 159 patients; 15 (9%) were ETMR not otherwise specified. In patients treated with curative intent, event-free survival was 57% (95% CI 47–68) at 6 months and 31% (21–42) at 2 years; overall survival was 29% (20–38) at 2 years and 27% (18–37) at 4 years. Overall survival was associated with non-metastatic disease (HR 0·48, 95% CI 0·28–0·80; p=0·0057) and non-brainstem location (0·42 [0·22–0·81]; p=0·013) on univariate analysis, as well as with gross total resection (0·30, 0·16–0·58; p=0·0014), high-dose chemotherapy (0·35, 0·19–0·67; p=0·0020), and radiotherapy (0·21, 0·10–0·41; p<0·0001) on multivariable analysis. 2-year event-free and overall survival was 0% at 2 years in patients treated with conventional chemotherapy without radiotherapy (regardless of surgery extent), and 21% (95% CI 1–41) and 30% (6–54), respectively, in patients treated with high-dose chemotherapy, and gross total resection without radiotherapy. 2-year event-free survival in patients treated with high-dose chemotherapy and radiotherapy was 66% (95% CI 39–93) for patients with gross total resection and 44% (7–81) for patients with sub-total resection. 2–5-year overall survival was 66% (95% CI 33–99, p=0·038) for patients with gross total resection and 67% (36–98, p=0·0020) for patients with sub-total resection. Interpretation Prompt molecular diagnosis and post-surgical treatment with intensive multi-modal therapy tailored to patient-specific risk features could improve ETMR survival. Funding Canadian Institute of Health Research, Canada Research Chair Awards, Australian Lions Childhood Cancer Research Foundation, Spanish Society of Pediatrics, Consejería de Salud y Familias de la Junta de Andalucía, Miracle Marnie, Phoebe Rose Rocks, Tali's Funds, Garron Cancer Centre, Grace's Walk, Meagan's Hug, Brainchild, Nelina's Hope, and Jean Martel Foundation." @default.
• W3202801096 created "2021-10-11" @default.
• W3202801096 creator A5000685371 @default.
• W3202801096 creator A5001406805 @default.
• W3202801096 creator A5002069227 @default.
• W3202801096 creator A5002642776 @default.
• W3202801096 creator A5002892990 @default.
• W3202801096 creator A5002952095 @default.
• W3202801096 creator A5003268046 @default.
• W3202801096 creator A5003479459 @default.
• W3202801096 creator A5003950778 @default.
• W3202801096 creator A5005290498 @default.
• W3202801096 creator A5005366116 @default.
• W3202801096 creator A5005700148 @default.
• W3202801096 creator A5006933141 @default.
• W3202801096 creator A5007291376 @default.
• W3202801096 creator A5008401630 @default.
• W3202801096 creator A5008641102 @default.
• W3202801096 creator A5009121120 @default.
• W3202801096 creator A5009590404 @default.
• W3202801096 creator A5010939758 @default.
• W3202801096 creator A5012381044 @default.
• W3202801096 creator A5012736355 @default.
• W3202801096 creator A5012891627 @default.
• W3202801096 creator A5013473072 @default.
• W3202801096 creator A5014150262 @default.
• W3202801096 creator A5014191604 @default.
• W3202801096 creator A5015881084 @default.
• W3202801096 creator A5016923180 @default.
• W3202801096 creator A5017144621 @default.
• W3202801096 creator A5017433026 @default.
• W3202801096 creator A5018379179 @default.
• W3202801096 creator A5019103647 @default.
• W3202801096 creator A5019140507 @default.
• W3202801096 creator A5019557839 @default.
• W3202801096 creator A5020204751 @default.
• W3202801096 creator A5020571536 @default.
• W3202801096 creator A5020920424 @default.
• W3202801096 creator A5021121537 @default.
• W3202801096 creator A5022310517 @default.
• W3202801096 creator A5023203827 @default.
• W3202801096 creator A5024438803 @default.
• W3202801096 creator A5025058720 @default.
• W3202801096 creator A5025567999 @default.
• W3202801096 creator A5026881155 @default.
• W3202801096 creator A5027426012 @default.
• W3202801096 creator A5027678095 @default.
• W3202801096 creator A5027769573 @default.
• W3202801096 creator A5029157696 @default.
• W3202801096 creator A5029328183 @default.
• W3202801096 creator A5029878147 @default.
• W3202801096 creator A5030100924 @default.
• W3202801096 creator A5033190757 @default.
• W3202801096 creator A5033276498 @default.
• W3202801096 creator A5033742371 @default.
• W3202801096 creator A5034672065 @default.
• W3202801096 creator A5035490206 @default.
• W3202801096 creator A5035544487 @default.
• W3202801096 creator A5037569533 @default.
• W3202801096 creator A5039750788 @default.
• W3202801096 creator A5039794905 @default.
• W3202801096 creator A5039839388 @default.
• W3202801096 creator A5040379779 @default.
• W3202801096 creator A5040474922 @default.
• W3202801096 creator A5040595262 @default.
• W3202801096 creator A5041812677 @default.
• W3202801096 creator A5041913264 @default.
• W3202801096 creator A5042255572 @default.
• W3202801096 creator A5042275051 @default.
• W3202801096 creator A5043001715 @default.
• W3202801096 creator A5043261933 @default.
• W3202801096 creator A5043812430 @default.
• W3202801096 creator A5044663377 @default.
• W3202801096 creator A5046321083 @default.
• W3202801096 creator A5046351275 @default.
• W3202801096 creator A5048228345 @default.
• W3202801096 creator A5048605189 @default.
• W3202801096 creator A5049032455 @default.
• W3202801096 creator A5049179921 @default.
• W3202801096 creator A5049721824 @default.
• W3202801096 creator A5050551518 @default.
• W3202801096 creator A5050917634 @default.
• W3202801096 creator A5051313596 @default.
• W3202801096 creator A5051466129 @default.
• W3202801096 creator A5051624965 @default.
• W3202801096 creator A5051661368 @default.
• W3202801096 creator A5052649527 @default.
• W3202801096 creator A5053563254 @default.
• W3202801096 creator A5053902605 @default.
• W3202801096 creator A5055460959 @default.
• W3202801096 creator A5055468599 @default.
• W3202801096 creator A5055909207 @default.
• W3202801096 creator A5056347942 @default.
• W3202801096 creator A5057151909 @default.
• W3202801096 creator A5057499262 @default.
• W3202801096 creator A5058720693 @default.
• W3202801096 creator A5058905503 @default.
• W3202801096 creator A5059000453 @default.

• next